Navigation Links
Oncos Therapeutics Granted Orphan Drug Designation for CGTG-102 in Soft Tissue Sarcoma (STS) by FDA and EMA
Date:7/31/2013

HELSINKI, Finland, July 31, 2013 /PRNewswire/ --

Oncos Therapeutics Ltd, a private, clinical-stage biotechnology company focused on the development and commercialization of targeted oncolytic immunotherapies for solid tumors, announced today that the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) have granted orphan drug designation for CGTG-102, a granulocyte-macrophage colony stimulating factor-coding oncolytic adenovirus (Ad5/3-D24-GMCSF) for the treatment of soft tissue sarcoma.

     (Logo: http://photos.prnewswire.com/prnh/20130731/630919)

"We are pleased to receive orphan drug designations for CGTG-102 from the two leading regulatory agencies in the world. These designations confirm the need for developing novel therapies for rare cancers and are an important step in the development of CGTG-102" ,said Frans Wuite, M.D., President and Chief Executive Officer of Oncos.

Orphan Drug Designation applies to drugs that seek to treat rare diseases or conditions for which there may be few adequate therapies. In USA, the designation will provide Oncos with the opportunity of seven years of marketing exclusivity, grant funding to defray costs of clinical trial expenses, tax credits for clinical research expenses and potential waiver of the FDA's application user fee. Similarly, incentives are provided for Europe by EMA, which include fee reductions on future activities and the potential for 10 years market exclusivity.

About Soft Tissue Sarcoma

Soft tissue sarcoma is estimated to affect 3-4 in 10,000 people in the EU and US. About 50% of soft tissue sarcomas are found in the early stage and advanced stage patients have an average overall survival of 13 months with today's standard of care. Several efforts to develop additional chemotherapeutics for STS have failed, including two products in Phase III development this year. Novel therapies with a different mechanism of action are therefore needed.

About CGTG-102

Oncos' lead product candidate, CGTG-102, is an oncolytic immunotherapy based on a purposefully modified, GM-CSF encoding adenovirus that selectively replicates in tumor cells and eventually kills them. Upon tumor cell death, newly synthesized viruses are released and infect neighboring tumor cells. Simultaneously, tumor antigens are exposed activating a tumor specific, systemic response by the patient's immune system. This response is further enhanced by the CGTG-102 induced production of GM-CSF in tumor cells.
A Phase I study with CGTG-102, will be completed this year and Phase II studies are scheduled to start in 2014. Prior to the Phase I study, 115 patients with chemotherapy refractory solid tumors had been treated with CGTG-102 in an individualized treatment program regulated by the Finnish Medicines Agency as determined by the EU Regulation on Advanced Therapy Medicinal Products, EC/1394/2007.

About Oncos Therapeutics

Oncos Therapeutics Ltd is a privately owned, clinical-stage biotechnology company focused on the development and commercialization of targeted oncolytic immunotherapy products for solid tumors. The company's lead investor is HealthCap, one of the largest specialized providers of venture capital within life sciences in Europe. Oncos is headquartered in Helsinki, Finland and has an office in Switzerland. For more information about Oncos, please visit http://www.oncos.com.

 


'/>"/>
SOURCE Oncos Therapeutics Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec Medical Updates Analysis of Interim Data for Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
2. OncoSec Medical to Present at the HemOnc Today Melanoma and Cutaneous Malignancies Meeting in New York
3. OncoSec Medical to Present at the 25th Annual Roth Conference
4. OncoSec Medical Promotes Veronica Vallejo to Chief Financial Officer
5. OncoSec Medical to Present at the 15th Annual BIO CEO & Investor Conference
6. OncoSec Medical to Present at Noble Financial Capital Markets Ninth Annual Equity Conference on January 22
7. OncoSec Medical Announces $7.2 Million Public Offering
8. OncoSec Medical to Present Data at DNA Vaccines 2012 Conference
9. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
10. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
11. OncoSec to Present at Upcoming Healthcare and Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 11, 2017  BioPharmX Corporation (NYSE MKT: BPMX) researchers ... an innovative way to use nonlinear optical imaging to ... new drugs. ... will show how researchers from BioPharmX and the Wellman ... used a suite of imaging techniques in what is ...
(Date:10/10/2017)... Pa. , Oct. 10, 2017   West ... in innovative solutions for injectable drug administration, today shared ... West,s ID Adapter for improving the intradermal administration of ... Fourth Skin Vaccination Summit in May 2017 by Dr. ... Lead, Polio Department, World Health Organization (WHO), and recently ...
(Date:10/4/2017)... 4, 2017 OBP Medical , ... medical devices, today announced regulatory approval from ... (or Agência Nacional de Vigilância Sanitária (ANVISA)) to ... surgical retractor with integrated LED light source and ... and exposure of a tissue pocket or cavity ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud to ... unique items from across the nation, this holiday-themed event will raise funds and awareness ... VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – 5:00 ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... be giving viewers the lowdown on sciatica in a new episode of "Success ... focuses on current events and innovation and investigates each subject in-depth with passion ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare ... program management, will showcase a range of technology and learning solutions at the ... Convention and Expo to be held October 14–18, 2017 at the Mandalay Bay ...
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the ... medical article to the newly revamped Cosmetic Town journal section, featuring ... transplant procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi ...
Breaking Medicine News(10 mins):